Have you recently evaluated a patient for uveitis? Or have you detected an intraocular tumor in a routine retinal evaluation? As retina specialists, we see a wide variety of patients with a multitude of clinical findings. Intraocular inflammation affecting the posterior and/or anterior segment of the eye is often referred to the retina specialist, especially in the setting of macular edema. In addition, intraocular tumors are challenging clinical cases that are referred to us for further evaluation and management.

This issue of Retinal Physician highlights important topics in ocular oncology and uveitis. Drs. Kevin Allan and Arun Singh discuss uveal melanoma and the potential role of proteomics in tumor diagnosis. Proteomics involves analysis of proteins in the blood or ocular fluids. These real-time protein signals may help physicians counsel patients about the type of tumor present and its prognosis and may even help guide therapy. In addition, Drs. Singh and Soumaya Bouhout review genetic testing in retinoblastoma and help us understand how molecular profiling may aid in the diagnosis and prognosis of the disease. Finally, Drs. Singh and Hannah Chen discuss radiation retinopathy, which commonly occurs after plaque brachytherapy. They review the established and investigational approaches to managing radiation retinopathy. In the coding column, Ms. Elizabeth Cifers reviews the billing codes for ocular tumors.

Drs. William Bloom and Ana Suelves provide a summary of the evolving treatment strategies for noninfectious uveitis. Intraocular inflammation cases can lead to chronic vision loss and it’s important to have the correct diagnosis and offer the most efficacious and safe therapy. The authors provide the latest information on advances in corticosteroid delivery, and then discuss systemic immunomodulation. In addition, they review pipeline therapies in clinical trials. Drs. Suelves and Alissa Belzie provide a review of JIA-associated uveitis in adults. They discuss how the condition can present with persistent inflammation, the need for chronic treatment, and the cumulative effects of this childhood disease. And in a feature you’ll find at retinalphysician.com, Dr. Howard Fine discusses practical strategies for integrating injectable corticosteroids into the treatment of noninfectious ocular inflammation.

I appreciate all our expert contributors who have graciously shared their knowledge. Their hard work and generosity are essential to the success of this journal. Thank you for taking the time to read Retinal Physician—I am grateful for your partnership. RP